Total Revenue
Eli Lilly Total Revenue increased by 2.6% to $19.80B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 55.5%, from $12.73B to $19.80B. Over 4 years (FY 2021 to FY 2025), Total Revenue shows an upward trend with a 23.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market demand or successful price increases, while a decrease suggests market saturation or competitive pressure.
Detailed definition
The total amount of income generated by the sale of goods or services related to the company's primary operations. For a...
Peer comparison
Peer technology firms typically report this as Net Sales or Total Revenue, reflecting the scale of their market reach.
total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.74B | $6.77B | $8.00B | $7.81B | $6.49B | $6.94B | $7.30B | $6.96B | $8.31B | $9.50B | $9.35B | $8.77B | $11.30B | $11.44B | $13.53B | $12.73B | $15.56B | $17.60B | $19.29B | $19.80B |
| QoQ Change | — | +0.5% | +18.1% | -2.4% | -16.9% | +7.0% | +5.2% | -4.7% | +19.4% | +14.3% | -1.5% | -6.3% | +28.9% | +1.2% | +18.3% | -5.9% | +22.2% | +13.1% | +9.6% | +2.6% |
| YoY Change | — | — | — | — | -3.7% | +2.5% | -8.7% | -10.9% | +28.1% | +36.8% | +28.1% | +26.0% | +36.0% | +20.4% | +44.7% | +45.2% | +37.6% | +53.9% | +42.6% | +55.5% |
Product Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Mounjaro | $3.09B | $3.11B | $3.53B | $3.84B | $5.20B | $6.52B | $7.41B | $8.66B |
| Zepbound | $1.24B | $1.26B | $1.91B | $2.31B | $3.38B | $3.59B | $4.26B | $4.16B |
| Verzenio | $1.33B | $1.37B | $1.56B | $1.16B | $1.49B | $1.47B | $1.60B | $1.30B |
| Jardiance | $769.60M | $686.40M | $1.20B | $1.01B | $690.00M | $959.00M | $768.60M | $1.11B |
| Other oncology | $299.10M | $324.30M | $427.30M | $788.60M | $924.30M | $937.40M | $1.00B | $966.00M |
| Trulicity | $1.25B | $1.30B | $1.25B | $1.10B | $1.09B | $1.05B | $1.04B | $919.00M |
| Other cardiometabolic health | $1.17B | $1.05B | — | $944.80M | $980.40M | $1.06B | $1.02B | $905.00M |
| Taltz | $824.70M | $879.60M | $952.00M | $761.90M | $847.60M | $901.50M | $1.05B | $733.00M |
| Other immunology | $30.00M | $55.30M | — | $326.10M | $408.00M | $460.90M | $489.00M | $470.00M |
| Neuroscience | $339.50M | $351.80M | $393.00M | $272.10M | $344.00M | $315.70M | $459.20M | $382.00M |
| Baqsimi | $12.40M | $13.40M | — | — | — | — | — | — |
| Basaglar® | $180.80M | $161.60M | $176.90M | — | — | — | — | — |
| Cialis® | $87.70M | $91.50M | — | — | — | — | — | — |
| COVID-19 Antibodies | — | — | $0.00 | — | — | — | — | — |
| Cyramza® | $248.90M | $236.00M | $258.40M | — | — | — | — | — |
| Emgality® | $192.00M | $202.90M | $249.80M | — | — | — | — | — |
| Erbitux® | $155.80M | $152.00M | $175.00M | — | — | — | — | — |
| Forteo® | $69.90M | $118.10M | — | — | — | — | — | — |
| Humalog® | $631.60M | $534.60M | $619.90M | — | — | — | — | — |
| Humulin® | $223.60M | $207.10M | $280.20M | — | — | — | — | — |
| Olumiant | $227.70M | $250.80M | $261.50M | — | — | — | — | — |
| Other | $207.60M | $262.80M | $190.70M | — | $201.50M | $337.20M | $191.40M | — |
| Other neuroscience | $147.50M | $117.20M | $58.60M | — | — | — | — | — |
| Tyvyt | $123.00M | $150.20M | $136.10M | — | — | — | — | — |
| Zyprexa | — | $31.70M | — | — | — | — | — | — |
| Total | $11.30B | $11.44B | $13.53B | $12.73B | $15.56B | $17.60B | $19.29B | $19.80B |
Alimta®, Baqsimi, Basaglar®, Cialis®, COVID-19 Antibodies, Cyramza®, Emgality®, Erbitux®, Forteo®, Humalog®, Humulin®, Olumiant, Other, Other diabetes, Other diabetes and obesity, Other neuroscience, Trajenta BI, Tyvyt, Zyprexa were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Reportable Segment | $12.73B | $15.56B | $17.60B | $19.29B | $19.80B |
| Total | $12.73B | $15.56B | $17.60B | $19.29B | $19.80B |
Geographic Breakdown
| Segment | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Outside U.S. | — | — | — | — | — | — | — | $7.68B |
| Europe | $1.44B | $1.40B | $1.63B | $2.39B | $2.57B | $3.50B | — | $3.65B |
| Rest of world | — | — | — | $997.40M | $1.18B | $1.69B | $2.19B | $2.77B |
| Other foreign countries | $892.90M | $1.21B | $1.11B | — | — | — | — | — |
| Total | $8.77B | $11.30B | $11.44B | $12.73B | $15.56B | $17.60B | $19.29B | $19.80B |
Other foreign countries was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
Total Revenue at Other Companies
Frequently Asked Questions
- What is Eli Lilly's total revenue?
- Eli Lilly (LLY) reported total revenue of $19.80B in Q1 2026.
- How has Eli Lilly's total revenue changed year-over-year?
- Eli Lilly's total revenue increased by 55.5% year-over-year, from $12.73B to $19.80B.
- What is the long-term trend for Eli Lilly's total revenue?
- Over 4 years (2021 to 2025), Eli Lilly's total revenue has grown at a 23.2% compound annual growth rate (CAGR), from $28.32B to $65.18B.
- What does total revenue mean?
- The total amount of money a company brings in from selling its products and services.